NewAmsterdam Pharma (NASDAQ:NAMS) Raised to Strong-Buy at BMO Capital Markets

by · The Markets Daily

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) was upgraded by BMO Capital Markets to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

A number of other research firms have also recently weighed in on NAMS. Jefferies Financial Group restated a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday. Royal Bank Of Canada increased their price target on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $49.42.

View Our Latest Report on NewAmsterdam Pharma

NewAmsterdam Pharma Trading Up 9.0%

Shares of NASDAQ:NAMS opened at $32.34 on Monday. NewAmsterdam Pharma has a 52 week low of $21.14 and a 52 week high of $42.21. The company’s 50 day moving average is $33.17 and its two-hundred day moving average is $32.95. The company has a market cap of $3.78 billion, a PE ratio of -18.07 and a beta of 0.08.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The firm had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. As a group, equities research analysts expect that NewAmsterdam Pharma will post -1.78 EPS for the current year.

Insider Activity

In other news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total value of $2,319,850.00. Following the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $869,158.57. The trade was a 72.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 12.74% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its holdings in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares during the period. Geode Capital Management LLC increased its stake in NewAmsterdam Pharma by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock valued at $3,590,000 after buying an additional 437 shares during the period. The Manufacturers Life Insurance Company raised its position in NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after buying an additional 544 shares during the last quarter. Farther Finance Advisors LLC raised its position in NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after buying an additional 708 shares during the last quarter. Finally, AlphaCentric Advisors LLC lifted its stake in shares of NewAmsterdam Pharma by 6.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company’s stock worth $469,000 after acquiring an additional 925 shares during the period. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

(Get Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

Featured Articles